Emerging data also suggest that activation of the NRG1-ErbB3 pathway may contribute to resistance to other targeted therapies, such as lorlatinib in ALK-positive NSCLC [149]. The gene discussed is ERBB3; the disease is non-small cell lung carcinoma.